NASDAQ:ALXO ALX Oncology (ALXO) Stock Price, News & Analysis $6.05 -0.05 (-0.82%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.99▼$6.3850-Day Range$5.45▼$15.0052-Week Range$3.94▼$17.83Volume736,318 shsAverage Volume629,602 shsMarket Capitalization$315.21 millionP/E RatioN/ADividend YieldN/APrice Target$19.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get ALX Oncology alerts: Email Address ALX Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside225.1% Upside$19.67 Price TargetShort InterestBearish26.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 3 Articles This WeekInsider TradingSelling Shares$873,346 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.89) to ($2.73) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.19 out of 5 starsMedical Sector416th out of 936 stocksPharmaceutical Preparations Industry190th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingALX Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageALX Oncology has only been the subject of 2 research reports in the past 90 days.Read more about ALX Oncology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted26.02% of the float of ALX Oncology has been sold short.Short Interest Ratio / Days to CoverALX Oncology has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in ALX Oncology has recently increased by 40.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldALX Oncology does not currently pay a dividend.Dividend GrowthALX Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALXO. Previous Next 3.7 News and Social Media Coverage News SentimentALX Oncology has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ALX Oncology this week, compared to 2 articles on an average week.Search Interest8 people have searched for ALXO on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows3 people have added ALX Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ALX Oncology insiders have sold 753.21% more of their company's stock than they have bought. Specifically, they have bought $102,360.00 in company stock and sold $873,346.00 in company stock.Percentage Held by Insiders33.40% of the stock of ALX Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.97% of the stock of ALX Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ALX Oncology's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ALX Oncology are expected to grow in the coming year, from ($2.89) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ALX Oncology is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ALX Oncology is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioALX Oncology has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ALX Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About ALX Oncology Stock (NASDAQ:ALXO)ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Read More ALXO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALXO Stock News HeadlinesJuly 16, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $158,000.00 in StockJuly 10, 2024 | insidertrades.comALX Oncology Holdings Inc. (NASDAQ:ALXO) CAO Sells $10,026.50 in StockJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 4, 2024 | insidertrades.comInsider Selling: ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells 3,273 Shares of StockJuly 26 at 2:40 AM | americanbankingnews.comALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by AnalystsJune 2, 2024 | globenewswire.comALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerMay 29, 2024 | globenewswire.comALX Oncology Announces Participation in the Jefferies Global Healthcare ConferenceMay 24, 2024 | markets.businessinsider.comBuy Rating for ALX Oncology Amid Impressive Evorpacept and Padcev Combination Trial ResultsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 16, 2024 | finance.yahoo.comInsider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells SharesMay 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), ALX Oncology Holdings (ALXO) and Quoin Pharmaceuticals (QNRX)May 10, 2024 | finance.yahoo.comALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...May 10, 2024 | investorplace.comALXO Stock Earnings: ALX Oncology Holdings Beats EPS for Q1 2024May 9, 2024 | globenewswire.comALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | globenewswire.comALX Oncology Appoints Allison Dillon as Chief Business OfficerMay 3, 2024 | msn.comRelay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09MApril 30, 2024 | finance.yahoo.comALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerApril 24, 2024 | globenewswire.comALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingSee More Headlines Receive ALXO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALXO CUSIPN/A CIK1810182 Webwww.alxoncology.com Phone650-466-7125FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$19.67 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+225.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.41% Return on Assets-72.16% Debt Debt-to-Equity Ratio0.06 Current Ratio5.21 Quick Ratio5.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book1.59Miscellaneous Outstanding Shares52,100,000Free Float34,699,000Market Cap$315.21 million OptionableOptionable Beta1.06 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Corey S. Goodman Ph.D. (Age 72)Executive Chairman Comp: $84kMr. Jason W. Lettmann (Age 47)CEO & Director Comp: $60.5kDr. Jaume Pons Ph.D. (Age 57)Founder, President, Director & Chief Scientific Officer Comp: $856.29kMr. Peter S. Garcia M.B.A. (Age 62)Chief Financial Officer Comp: $631.11kDr. Sophia Randolph M.D. (Age 56)Ph.D., Chief Medical Officer & Director Comp: $637.24kDr. Michael Chang Ph.D.Vice President of OperationsMs. Shelly Pinto (Age 47)Senior VP of Finance & Chief Accounting Officer Comp: $508.26kDr. Christopher Byrd J.D.Ph.D., General CounselDr. Athanasios Tsiatis M.D.Senior Vice President of Clinical DevelopmentDr. Lin Yeong-Liang M.D.M.S., Senior Vice President of Drug Safety & PharmacovigilanceMore ExecutivesKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIRI-MabNASDAQ:IMABANI PharmaceuticalsNASDAQ:ANIPArcus BiosciencesNYSE:RCUSArdelyxNASDAQ:ARDXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 25,199 shares on 7/26/2024Ownership: 0.201%SG Americas Securities LLCSold 3,400 shares on 7/12/2024Ownership: 0.039%Jaume PonsSold 20,000 sharesTotal: $158,000.00 ($7.90/share)Shelly PintoSold 1,823 sharesTotal: $10,026.50 ($5.50/share)Sophia RandolphSold 3,273 sharesTotal: $19,048.86 ($5.82/share)View All Insider TransactionsView All Institutional Transactions ALXO Stock Analysis - Frequently Asked Questions How have ALXO shares performed this year? ALX Oncology's stock was trading at $14.89 at the beginning of 2024. Since then, ALXO shares have decreased by 59.4% and is now trading at $6.05. View the best growth stocks for 2024 here. How were ALX Oncology's earnings last quarter? ALX Oncology Holdings Inc. (NASDAQ:ALXO) issued its quarterly earnings results on Thursday, May, 9th. The company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.16. When did ALX Oncology IPO? ALX Oncology (ALXO) raised $128 million in an initial public offering (IPO) on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor acted as the underwriters for the IPO and LifeSci Capital was co-manager. Who are ALX Oncology's major shareholders? Top institutional investors of ALX Oncology include Bank of New York Mellon Corp (0.20%), SG Americas Securities LLC (0.04%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Jaume Pons, Sophia Randolph, Jason Lettmann, Peter S Garcia, Shelly Pinto and Lsv Associates, Llc. View institutional ownership trends. How do I buy shares of ALX Oncology? Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ALX Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK) and Abbott Laboratories (ABT). This page (NASDAQ:ALXO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.